Platinum-DNA Adducts in Children After Cisplatin and Carboplatin Therapy
Author Information
Author(s): B Peng, MJ Tilby, MW English, L Price, ADJ Pearson, AV Boddy, DR Newell
Primary Institution: The University of Newcastle upon Tyne
Hypothesis
What is the relationship between platinum-DNA adduct levels and pharmacokinetics in children receiving cisplatin and carboplatin?
Conclusion
Cisplatin produces higher levels of platinum-DNA adducts than carboplatin in children, despite carboplatin having a higher unbound drug AUC.
Supporting Evidence
- Carboplatin produced lower levels of immunoreactive adducts than cisplatin.
- Adduct levels were weakly correlated with the area under the unbound drug concentration vs time curve.
- Interindividual variation in Pt-DNA adduct levels was primarily determined by factors other than AUC.
Takeaway
This study looked at how two cancer drugs, cisplatin and carboplatin, affect children's blood cells and how much they stick to DNA. It found that cisplatin sticks more than carboplatin.
Methodology
The study measured platinum-DNA adducts in blood samples from children receiving cisplatin and/or carboplatin using ELISA and analyzed pharmacokinetics through blood sampling at various time points.
Potential Biases
Potential bias due to the influence of other chemotherapy agents on the results.
Limitations
The study had a small sample size and could not assess the relationship between adduct levels and treatment response due to the complexity of chemotherapy protocols.
Participant Demographics
24 children (6 females, 18 males) with solid tumors receiving cisplatin and/or carboplatin.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website